The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Karl Semaan
No Relationships to Disclose
 
Liliana Ascione
No Relationships to Disclose
 
Jad El Masri
No Relationships to Disclose
 
Wassim Daoud Khatoun
No Relationships to Disclose
 
Mustafa Saleh
No Relationships to Disclose
 
Clara Steiner
Honoraria - Eisai Germany
Consulting or Advisory Role - Eisai Germany
 
Pablo Barrios
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Bohuslav Melichar
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/; Merck Serono; MSD
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Precede Bio; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Giuseppe Procopio
Honoraria - AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Iqvia/Gilead; Menarini/Ascenian Berlin; Menarini/Ascenian Berlin; Merck; MSD; MSD; Pfizer; Pfizer
Consulting or Advisory Role - ACCORD Healthcare Italia Srl; Advanced Accelerator Applications a Novartis Company; Astellas Pharma Global Development, Inc/IQVIA Ltd; Astellas Pharma S.p.A.; AstraZeneca; Astrazeneca e MSD; AstraZeneca Romania; Bayer; BEAUFOUR IPSEN FARMACÊUTICA LTDA; BMS; Bristol Myers Squibb; Bristol Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; ETHOS Srl; HPS – Health Publishing & Services Srl; Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; Jhnson&Johnson/Janssen CILAG SpA; MSD; MSD; MSD; MSD Oncology; MSD/ Icon; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer S.r.l.; Telix Pharmaceuticals Limited
Research Funding - AstraZeneca (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
Expert Testimony - AstraZeneca; IPSEN; IPSEN; MSD Italy
Other Relationship - AIRC (Inst); EC Horizon Europe (Inst); EC Horizon Europe (Inst); INT Milan (Inst); INT Milan cofunded by MSD (Inst); Italian Ministry of Health (Inst)
(OPTIONAL) Uncompensated Relationships - AIOM; ESMO; FICOG; MEET-URO
 
Omi Parikh
No Relationships to Disclose
 
Melissa Reimers
Consulting or Advisory Role - Astellas Pharma; Cicadea Biotech; Eisai; EMD Serono; Lilly; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; Daichi-Sanchyo; DYANIA HEALTH; EMD Serono; EMD Serono; Exelixis; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Sylvan Baca
Stock and Other Ownership Interests - Precede Bio
Consulting or Advisory Role - Precede Bio
Patents, Royalties, Other Intellectual Property - Patents related to subtyping cancer and selecting treatments using liquid biopsy.
 
Srinivas Viswanathan
No Relationships to Disclose
 
Prateek Khanna
No Relationships to Disclose
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Caris Life Sciences; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
(OPTIONAL) Uncompensated Relationships - AACR Scientific Advisory Council